Follow on Google News News By Tag * Gtcb * Hgsi * Dpdm * Gtc Biotherapeutics * Human Genome Sciences * Penny Stocks * Hot Stocks * Best Penny Stocks To Buy * Investor * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News | Penny Stocks Alert – Hot Stocks Alert for GTCB, HGSI, DPDMMobile Press Wire issues Hot Stocks and Penny Stocks alerts for emerging public companies on the move
By: MobilePressWire.com To Receive FREE Stock Alerts specially formatted for you mobile phone no matter where you are, please see below or go to http://www.mobilepresswire.com for more details. Human Genome Sciences, Inc. NEWS – January 9, 2009 Small Cap Alert: FDA Advisory Committee Recommends GTC Biotherapeutics' ATryn* GTC Biotherapeutics and OVATION Pharmaceuticals, Inc. released breaking news that the Blood Products Advisory Committee of the U.S. Food and Drug Administration indicated that ATryn is safe and efficacious for the prevention and treatment of venous thromboembolism in hereditary antithrombin deficient patients undergoing surgery or childbirth procedures. The FDA considers the recommendations of its Advisory Committees when making its determinations. If approved, ATryn will be the first recombinant human antithrombin available in the U.S. GTC Biotherapeutics, Inc. develops, supplies, and commercializes therapeutic proteins produced through transgenic animal technology. The company�s recombinant human antithrombin, ATryn, has been approved for use in Europe and has begun the review process in the United States under a rolling Biologics License Application. In addition to ATryn, it also develops a portfolio of recombinant human plasma proteins with known therapeutic properties. Investors are urged to look for early trading activity today as the stock closed Friday, January 9th, 2009 at $0.6785 a share. To read the entire release regarding the company's news and to sign up to get FREE alerts like this sent to your cellular device before others are able to view it, visit: http://mobilepresswire.com/ Human Genome Sciences NEWS – January 12, 2009 Investor Alert: Human Genome Sciences Begins Phase 2b Trial of Albuferon(R) Human Genome Sciences, Inc. operates as a biopharmaceutical company in the Unites States. The company develops protein and antibody drugs to treat hepatitis C, lupus, inhalation anthrax, cancer, and other immune-mediated diseases. Its primary products include Albuferon, which is in Phase 3 clinical trials for the treatment of hepatitis C, hepatitis B, and a range of cancers; LymphoStat-B, which is in Phase 3 clinical trials for the treatment of systemic lupus erythematosus, rheumatoid arthritis, and certain other autoimmune diseases; and ABthrax, a final stage development product, for the treatment of inhalation anthrax. The company is also developing various oncology products, such as HGS-ETR1 (mapatumumab) Investors are urged to look for early trading activity today as the stock closed Friday, January 9th, 2009 at $1.88 a share. To read the entire release regarding the company's recent announcement and to sign up to get FREE alerts like this sent to your cellular device before others are able to view it, visit: http://mobilepresswire.com/ Dolphin Digital Media NEWS - January 12, 2009 Small Cap Alert: Dolphin Digital Media Secures Initial Private Placement Funding Miami FL, Dolphin Digital Media, Inc. , released breaking news this morning that the company completed a $700,000 private placement of a budgeted $3,000,000 estimated financing requirement. Dolphin Digital Media, Inc. creates and manages social networking Web sites for children utilizing biometric identity authentication technology. It develops and operates secure on-line communities for young audiences surrounding the company's television programs for children, including Nickelodeon's top-rated series Zoey 101, Ned's Declassified School Survival Guide, and the mystery movie franchise Roxy Hunter. The company also operates Anne's World, the licensee of Annesdiary.com, a social networking site for girls aged 5-14. In addition, Dolphin Digital Media engages in the development and operation of playsonthenet.com, a global online theatre community for aspiring playwrights; Investors are urged to look for early trading activity today as the stock closed Friday, January 9th, 2009 at $0.80 a share. To read the entire release regarding the company's recent announcement and to sign up to get FREE alerts like this sent to your cellular device before others are able to view it, visit: http://mobilepresswire.com/ ABOUT MOBIWIRE MobiWire is solely owned and operated by Mobile Press Wire a leading news alert wire service for mobile phones subscribers. Mobile Press Wire offers FREE news alerts for its subscribers of publicly traded companies that wish to instantly announce special news to the investment community. Visit http://www.mobilepresswire.com for more details. GET NEWS NOW, GET NEWS FAST, GET NEWS BEFORE OTHERS... To get FREE Mobile Stock Alerts formatted especially for your cell phone; text the word "STOCKS" in the subject line to 68494. Please note subscribers are never charged any fees from Mobile Press Wire for signing up to receive public company alerts or canceling any of our services. Standard carrier SMS text messaging rates may apply. Please check with your wireless plan for further details. Subscribers are able to fully control the number of alerts they want to receive. Choose to get 1 a week, 2 a week, 5 a week and so on. Subscribers are also able to stop receiving alerts at anytime with no questions asked by texting the word STOP to 68494. Contact email: info@mobilepresswire.com URL: http://www.mobilepresswire.com Company: MobiWire # # # Mobile Media Technology Solutions. Utilizing proprietary SMS Text Message Services, we deliver breaking news alerts for Public Companies and Investor Relations Professionals via specially formatted text messages. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||
